FREE SHIPPING ON ORDERS OVER $150

fda stops tirzepatide compounding ban on compounded tirzepatide: Switch to name brand medications is fda stopping compounded tirzepatide

$26.15

Quantity
- +
Description

Results from Eli Lillys SURMOUNT-2 trial are in, and they further confirmed that its GLP-1 agonist tirzepatide (aka Mounjaro) drives meaningful weight loss among obese or overweight adults with type 2 diabetes

fda stops tirzepatide compounding ban on compounded tirzepatide: Switch to name brand medications is fda stopping compounded tirzepatide

Mechanism: GLP-1 receptor agonist

fda stops tirzepatide compounding ban on compounded tirzepatide: Switch to name brand medications is fda stopping compounded tirzepatide

She co-writes The Readout newsletter, and co-hosts STATs weekly biotech podcast, The Readout Loud

fda stops tirzepatide compounding ban on compounded tirzepatide: Switch to name brand medications is fda stopping compounded tirzepatide

I take 12.5 weekly

fda stops tirzepatide compounding ban on compounded tirzepatide: Switch to name brand medications is fda stopping compounded tirzepatide

J., Taype-Rondan, A., Tapia, J

fda stops tirzepatide compounding ban on compounded tirzepatide: Switch to name brand medications is fda stopping compounded tirzepatide

It pushes usage toward name-brand, FDA-approved possibilities for weight control.

fda stops tirzepatide compounding ban on compounded tirzepatide: Switch to name brand medications is fda stopping compounded tirzepatide

You may also like

recommand products